Thrive will commercialise a blood test for multiple early-stage cancers based on research at Johns Hopkins University, following a series A round backed by Blue Cross and Blue Shield Association.

US-based oncology diagnostics technology startup Thrive Earlier Detection launched yesterday with 110m in series A funding from investors including of health insurer Blue Cross and Blue Shield Association and diagnostics services provider Exact Sciences. The round was ┬áled by venture capital firm Third Rock Ventures and included Section 32, Casdin Capital, Biomatics Capital, Invus, Cowin…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.